DiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureHumanitiesInformation ScienceNamed GroupsHealth CarePublication CharacteristicsGeographicals
Clinical Trials, Phase III as TopicClinical Trials as TopicClinical Trials, Phase II as TopicTreatment OutcomeDouble-Blind MethodResearch DesignAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase I as TopicRandomized Controlled Trials as TopicDrug Administration SchedulePlacebosAntineoplastic AgentsControlled Clinical Trials as TopicDisease-Free SurvivalMulticenter Studies as TopicSurvival AnalysisClinical Trials, Phase IV as TopicPatient SelectionTime FactorsCisplatinProspective StudiesFluorouracilNeoplasmsCombined Modality TherapyDeoxycytidineFollow-Up StudiesQuality of LifeLung NeoplasmsEarly Termination of Clinical TrialsEndpoint DeterminationPaclitaxelSurvival RateClinical ProtocolsChemotherapy, AdjuvantSingle-Blind MethodTaxoidsNeoplasm StagingAntibodies, Monoclonal, HumanizedInfusions, IntravenousAdministration, OralClinical Trials Data Monitoring CommitteesDrug Therapy, CombinationBreast NeoplasmsDose-Response Relationship, DrugDisease ProgressionSample SizeCarcinoma, Non-Small-Cell LungVinblastineDrugs, InvestigationalKaplan-Meier EstimateCarboplatinDoxorubicinPrognosisNeoplasm MetastasisCyclophosphamideUnited StatesMedical OncologyLeucovorinPilot ProjectsAntibodies, MonoclonalSeverity of Illness IndexAntimetabolites, AntineoplasticMyoelectric Complex, MigratingCost-Benefit AnalysisTreatment FailureColorectal NeoplasmsEvidence-Based MedicineOrganoplatinum CompoundsDrug ApprovalRecurrenceOutcome Assessment (Health Care)Risk FactorsNauseaEpirubicinProportional Hazards ModelsVincristineMethotrexateNeoplasm Recurrence, LocalClinical Trial, Phase IIIRisk AssessmentResearch SubjectsAntineoplastic Agents, PhytogenicPatient ComplianceFeasibility StudiesRadiotherapy, AdjuvantQuestionnairesReproducibility of ResultsRemission InductionNeutropeniaDrug EvaluationEtoposideCamptothecinDrug CombinationsDrug-Related Side Effects and Adverse ReactionsEuropeNational Cancer Institute (U.S.)Biomedical ResearchAdenocarcinomaProstatic NeoplasmsQuinazolines